Ruben Willems, Lore Pil, Christina-Paulina Lambrinou, Jemina Kivelä, Katja Wikström, Esther M Gonzalez-Gil, Pilar De Miguel-Etayo, Anna Nánási, Csilla Semánová, Vicky Van Stappen, Greet Cardon, Kaloyan Tsochev, Violeta Iotova, Nevena Chakarova, Konstantinos Makrilakis, George Dafoulas, Patrick Timpel, Peter Schwarz, Yannis Manios, Lieven Annemans
Methodology of the health economic evaluation of the Feel4Diabetes-study
BMC endocrine disorders
purpose assess patient preference oral versus intravenous iv palliative chemotherapy ct strong preference would important qualityoflife issue patients methods structured intervieweradministered scenariobased questionnaire evaluated incurable cancer patients would likely receive palliative ct future using probability tradeoffs preference route administration evaluated diminishing treatment response results 103 assessable patients 92 preferred oral ct 10 preferred iv ct one preference patient preferences associated age sex site primary cancer previous ct experiences major reasons preferring oral ct convenience problems iv access needles better cttaking environment outside clinic regardless initial preference 70 patients willing accept lower response rate 74 willing accept shorter duration response retain initial preference although 99 patients preference 39 wanted specific treatment decision made primarily physicians 38 primarily 22 shared equally conclusion patients incurable cancer clear preference oral ct generally willing sacrifice efficacy preference almost 40 patients want make final treatment decisions